These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 24630925)
21. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875 [TBL] [Abstract][Full Text] [Related]
22. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846 [TBL] [Abstract][Full Text] [Related]
23. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. Pellecchia MT; Pivonello R; Salvatore E; Faggiano A; Barone P; De Michele G; Lombardi G; Colao A; Filla A Clin Endocrinol (Oxf); 2005 Apr; 62(4):428-33. PubMed ID: 15807873 [TBL] [Abstract][Full Text] [Related]
24. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ashour R; Jankovic J Mov Disord; 2006 Nov; 21(11):1856-63. PubMed ID: 16941460 [TBL] [Abstract][Full Text] [Related]
26. Putaminal hypointensity on T2*-weighted MR imaging is the most practically useful sign in diagnosing multiple system atrophy: A preliminary study. Sugiyama A; Ito S; Suichi T; Sakurai T; Mukai H; Yokota H; Yonezu T; Kuwabara S J Neurol Sci; 2015 Feb; 349(1-2):174-8. PubMed ID: 25619571 [TBL] [Abstract][Full Text] [Related]
27. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease. Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973 [TBL] [Abstract][Full Text] [Related]
28. [Clinical diagnostic criteria in Parkinson's disease and parkinsonian syndromes: review of the literature]. Vercueil L Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():14-22. PubMed ID: 10916032 [TBL] [Abstract][Full Text] [Related]
29. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease. Somme J; Gómez-Esteban JC; Tijero B; Berganzo K; Lezcano E; Zarranz JJ Clin Neurol Neurosurg; 2013 Aug; 115(8):1230-3. PubMed ID: 23253819 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Hussl A; Mahlknecht P; Scherfler C; Esterhammer R; Schocke M; Poewe W; Seppi K Mov Disord; 2010 Oct; 25(14):2444-9. PubMed ID: 20878992 [TBL] [Abstract][Full Text] [Related]
31. Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Worker A; Blain C; Jarosz J; Chaudhuri KR; Barker GJ; Williams SC; Brown R; Leigh PN; Simmons A PLoS One; 2014; 9(12):e114167. PubMed ID: 25463618 [TBL] [Abstract][Full Text] [Related]
32. Frontal deficits differentiate progressive supranuclear palsy from Parkinson's disease. Lee YE; Williams DR; Anderson JF J Neuropsychol; 2016 Mar; 10(1):1-14. PubMed ID: 25223526 [TBL] [Abstract][Full Text] [Related]
33. Orofacial apraxia in corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. Ozsancak C; Auzou P; Dujardin K; Quinn N; Destée A J Neurol; 2004 Nov; 251(11):1317-23. PubMed ID: 15592726 [TBL] [Abstract][Full Text] [Related]
35. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy]. Yoshita M; Hayashi M; Hirai S Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173 [TBL] [Abstract][Full Text] [Related]
36. Is clonidine-growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease? Mathias CJ; Kimber J; Watson L; Muthane U J Neurol; 2002 Apr; 249(4):488-9. PubMed ID: 11967661 [No Abstract] [Full Text] [Related]
37. Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Rusz J; Bonnet C; Klempíř J; Tykalová T; Baborová E; Novotný M; Rulseh A; Růžička E J Neurol; 2015; 262(4):992-1001. PubMed ID: 25683763 [TBL] [Abstract][Full Text] [Related]
38. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242 [TBL] [Abstract][Full Text] [Related]
39. Differential diagnosis of Parkinson's disease: a new blood test? Hiner BC Clin Med Res; 2006 Dec; 4(4):246-7. PubMed ID: 17210972 [No Abstract] [Full Text] [Related]